TransMedics Group, Inc. (TMDX) Quick Ratio (Acid-Test): 6.59
Is TransMedics Group, Inc.’s quick ratio (acid-test) high or low?
TransMedics Group, Inc.'s quick ratio (acid-test) of 6.59 is 18% below its 5-year average of 8.04, around the middle of its 5-year range (4.47–11.35).
As of Saturday, June 20, 2026. 6.59% below its 12-month average of 7.05.
TMDX Quick Ratio (Acid-Test) Chart
TMDX Average Quick Ratio (Acid-Test) Chart
TMDX Current vs Average Quick Ratio (Acid-Test) Chart
TMDX Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
6.59
QUICK RATIO (ACID-TEST) AVG TTM
7.05
QUICK RATIO (ACID-TEST) AVG 3Y
8.10
QUICK RATIO (ACID-TEST) AVG 5Y
8.04
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.59%
CURRENT VS 3Y AVG
-18.62%
CURRENT VS 5Y AVG
-17.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 6.59 | 7.05 | 8.10 | 8.04 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 1.03 | 0.89 | 0.95 | 0.97 |
| 23andMe Holding Co. (ME)vs › | $15.31M | 0.70 | 1.29 | 2.30 | 2.23 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 4.19 | 4.52 | 4.42 | 3.69 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 1.61 | 1.56 | 2.48 | 3.39 |
| Tempus AI, Inc. (TEM)vs › | $8.87B | 3.00 | 2.58 | 2.23 | 3.05 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 1.02 | 1.07 | 1.10 | 1.11 |
| Baxter International Inc. (BAX)vs › | $10.27B | 1.56 | 1.31 | 1.23 | 1.40 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.37 | 0.33 | 0.35 | 0.35 |
| Revvity, Inc. (RVTY)vs › | $11.16B | 1.40 | 2.21 | 2.02 | 1.79 |
Liquidity Comparison
Quick Ratio
6.59
Excludes inventory
Current Ratio
7.14
Includes inventory
TransMedics Group, Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for TransMedics Group, Inc. (TMDX)?
- The quick ratio (acid-test) for TMDX stock is 6.59.
- Is TransMedics Group, Inc.'s quick ratio (acid-test) high or low?
- TransMedics Group, Inc.'s quick ratio (acid-test) of 6.59 is 18% below its 5-year average of 8.04, around the middle of its 5-year range (4.47–11.35).
- What is the TTM average quick ratio (acid-test) for TransMedics Group, Inc. (TMDX)?
- The TTM average quick ratio (acid-test) for TMDX stock is 7.05.
- What is the 3Y average quick ratio (acid-test) for TransMedics Group, Inc. (TMDX)?
- The 3Y average quick ratio (acid-test) for TMDX stock is 8.10.
- What is the 5Y average quick ratio (acid-test) for TransMedics Group, Inc. (TMDX)?
- The 5Y average quick ratio (acid-test) for TMDX stock is 8.04.
TransMedics Group, Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 6.59 |
| 2024-12-31 | 7.52 |
| 2023-12-31 | 8.49 |
| 2022-12-31 | 9.79 |
| 2021-12-31 | 4.47 |
| 2020-12-31 | 11.35 |
| 2019-12-31 | 5.51 |
| 2018-12-31 | 2.03 |
| 2017-12-31 | 2.39 |
| 2016-12-31 | 5.23 |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein